Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)

Sarepta Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $116.0 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million in Q1 2026; TTM through Mar 2026 was $116.0 million, a 158.67% increase from a year earlier, with the FY2025 full-year figure at $443.4 million, up 240.4% from the prior year.
• Current Deferred Revenue slipped to $116.0 million in Q1 2026 per SRPT's latest filing, from $443.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $485.4 million in Q3 2025 and bottomed at $22.5 million in Q3 2023.
• The 5-year median for Current Deferred Revenue is $89.2 million (2022), against an average of $148.2 million.
• Across the five-year window, Current Deferred Revenue slumped 74.79% in 2023 and soared 464.6% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $89.2 million in 2022, then tumbled by 43.51% to $50.4 million in 2023, then soared by 158.36% to $130.3 million in 2024, then soared by 240.4% to $443.4 million in 2025, then plunged by 73.83% to $116.0 million in 2026.
• Per Business Quant, the three latest SRPT Current Deferred Revenue figures stand at $116.0 million (Q1 2026), $443.4 million (Q4 2025), and $485.4 million (Q3 2025).